Positron
emission
tomography/computed
tomography
(PET/CT)
using
18F-fluorodeoxyglucose
([18F]-FDG)
is
a
widely
adopted
imaging
modality
for
detecting
hypermetabolic
lesions.
However,
emerging
positron-emitting
tracers,
such
as
radiopharmaceuticals
featuring
fibroblast
activation
protein
(FAP)
inhibitors
(FAPI)
labeled
with
[18F]
or
[68Ga],
have
opened
new
avenues
in
nuclear
medicine.
This
case
report
focuses
on
the
unique
behavior
of
[68Ga]-FAPI
bilateral
gluteal
myositis
ossificans,
an
infrequent
condition
characterized
by
soft
tissue
ossification.
A
45-year-old
woman
gastric
adenocarcinoma
underwent
subtotal
gastrectomy
and
received
neoadjuvant
adjuvant
chemotherapy;
PET
revealed
metastatic
processes
unexpected
avid
intramuscular
ossifications
pelvic
thigh
muscles.
Even
though
there
was
no
history
trauma,
patient
diagnosed
marked
non-cancerous
ectopic
ossifications.
Diagnosis
relies
history,
radiology,
and/or
histology.
FAPI
imaging,
increasingly
used
inflammatory
infectious
diseases,
can
exhibit
uptake
benign
conditions,
including
those
involving
bones
joints.
first
to
document
incidental
ossificans.
The
robust
activity
ossificans
highlights
importance
considering
context
calcifications
intense
uptake.
Diagnostics,
Год журнала:
2025,
Номер
15(2), С. 218 - 218
Опубликована: Янв. 19, 2025
Background/Objectives:
Over
the
past
four
years,
68Ga-fibroblast
activation
protein
inhibitor
(FAPI)
positron
emission
tomography/computed
tomography
(PET/CT)
has
been
established
at
a
tertiary
cancer
care
facility
in
Jordan.
This
retrospective
study
aims
to
explore
tracer
uptake
metrics
across
various
epithelial
neoplasms,
identify
diagnostic
pitfalls
associated
with
68Ga-FAPI
PET/CT,
and
evaluate
influence
of
PET/CT
staging
results
on
changes
therapeutic
intent
compared
gold
standard
molecular
imaging
modalities.
Methods:
A
total
48
patients
biopsy-confirmed
solid
tumors
underwent
77
examinations
for
assessment,
encompassing
neoplasms
originating
from
gastrointestinal
tract,
head
neck,
hepatobiliary
system,
pancreas,
breast,
lung.
Results:
Notably,
pancreaticobiliary
exhibited
highest
uptake,
mean
maximum
standardized
values
(SUVmax)
tumor-to-background
ratios
(TBR)
surpassing
10.
comparative
sub-analysis
PET
20
treatment-naïve
revealed
significant
correlation
between
tumor
grade
(Spearman’s
rho
0.83;
p
=
0.00001).
Importantly,
influenced
treatment
decisions
35.5%
cases,
primarily
resulting
an
escalation
management
plans.
220
challenges
were
identified
88.3%
scans,
predominantly
within
musculoskeletal
attributed
degenerative
(99
observations).
Conclusions:
comprehensive
analysis
highlights
potential
significance
oncological
strategy,
while
also
emphasizing
necessity
meticulous
interpretation
mitigate
challenges.
Cancers,
Год журнала:
2024,
Номер
16(11), С. 1974 - 1974
Опубликована: Май 23, 2024
The
objective
of
this
retrospective
study
is
to
assess
the
effectiveness
and
safety
two
beta-emitting
prostate-specific
membrane
antigen
(PSMA)
radioligands,
[177Lu]Lu
[161Tb]Tb,
in
heavily
treated
patients
with
metastatic
castration-resistant
prostate
cancer
(mCRPC).
A
total
148
cycles
PSMA
radioligand
therapy
were
given
53
at
a
specialized
care
center
Amman,
Jordan.
This
treatment
was
offered
following
exhaustion
all
prior
modalities.
Approximately
half
cases
(n
=
26)
demonstrated
an
initial
partial
response
therapy.
Moreover,
roughly
one-fourth
13)
exhibited
sustained
satisfactory
biochemical
response,
which
qualified
them
receive
six
maintain
continued
follow-up
for
additional
cycles.
reflected
by
adequate
(PSA)
decline
concomitant
evident
on
[68Ga]Ga-PSMA
positron
emission
tomography/computed
tomography
imaging.
minority
(n=
18;
34%)
experienced
side
effects.
Generally,
these
low-grade
self-limiting
toxicities.
endorses
previous
research
evidence
about
therapy's
efficacy.
It
also
provides
first
clinical
insight
from
Arab
ethnicity.
should
facilitate
promote
further
evidence,
both
regionally
internationally.
Journal of Nuclear Medicine,
Год журнала:
2024,
Номер
65(9), С. 1340 - 1342
Опубликована: Авг. 8, 2024
Radiopharmaceutical
therapy
(RPT)
is
established
as
an
innovative,
effective,
and
well-tolerated
treatment
platform
approved
for
well-differentiated
neuroendocrine
tumors
advanced
prostate
cancer
(PC)
being
investigated
in
many
other
cancers
such
breast,
lung,
thyroid
([1][1]–[3
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 310 - 310
Опубликована: Фев. 28, 2025
Background/Objectives:
Radiotheranostics
of
neurotensin
subtype
1
receptor
(NTS1R)-expressing
tumors,
like
pancreatic,
gastrointestinal,
or
prostate
cancer,
has
attracted
considerable
attention
in
recent
years.
Still,
the
fast
degradation
(NT)-based
radioligands,
by
angiotensin-converting
enzyme
(ACE),
neprilysin
(NEP),
and
other
proteases,
considerably
compromised
their
efficacy.
The
recently
introduced
[99mTc]Tc-DT11
(DT11,
N4-Lys(MPBA-PEG4)-Arg-Arg-Pro-Tyr-Ile-Leu-OH;
N4,
6-(carboxy)-1,4,8,11-tetraazaundecane)
displayed
promising
uptake
NTS1R-positive
tumors
mice
enhanced
resistance
to
both
ACE
NEP
virtue
lateral
MPBA-PEG4
(MPBA,
4-(4-methylphenyl)butyric
acid;
PEG4,
14-amino-3,6,9,12-tetraoxatetradecan-1-oic
acid)
chain
attached
ε-NH2
Lys7.
We
were
next
interested
investigating
whether
these
qualities
could
be
retained
DT14D,
likewise
modified
at
Lys7
but
carrying
universal
chelator
DOTA
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
via
a
(βAla)3
spacer
α-NH2
This
switch
enables
labeling
DT14D
with
wide
range
trivalent
radiometals
suitable
for
true
theranostic
applications,
not
restricted
diagnostic
imaging
lesions
only
single-photon
emission
computed
tomography
(SPECT).
Methods:
was
labeled
Ga-67
(a
surrogate
positron
radionuclide
Ga-68),
In-111
(for
SPECT),
Lu-177
(applied
radiotherapy).
resulting
radioligands
tested
NTS1R-expressing
pancreatic
cancer
AsPC-1
cells
models.
Results:
[67Ga]Ga/[111In]In/[177Lu]Lu-DT14D
high
affinity
human
NTS1R
internalization
cells.
They
remained
>70%
intact
5
min
after
entering
mice’s
circulation,
displaying
NTS1R-specific
xenografts.
Conclusions:
Suitably
side-chain
NT
analogs
show
metabolic
stability
hence
better
prospects
radiotheranostic
application
cancer.
Journal of Nuclear Medicine,
Год журнала:
2025,
Номер
unknown, С. jnumed.124.269215 - jnumed.124.269215
Опубликована: Март 27, 2025
Since
its
inception
in
2012,
the
Nuclear
Medicine
Global
Initiative
(NMGI)
of
Society
and
Molecular
Imaging
has
played
an
important
role
addressing
significant
challenges
field
nuclear
medicine
molecular
imaging.
The
first
3
projects
were
dedicated
to
standardizing
pediatric
practices,
global
radionuclide
access
availability,
assessing
educational
training
initiatives
on
theranostics
across
globe.
These
efforts
aimed
advance
human
health,
foster
worldwide
collaboration,
standardize
procedural
guidelines
enhance
quality
safety
practice.
In
latest
project,
NMGI
develop
a
unified
nomenclature
for
systemic
therapy
medicine,
diverse
terminology
currently
used.
An
online
survey
was
distributed
member
organizations,
drawing
participation
from
various
geographical
locations
disciplines.
anonymously
collected
responses
physicians,
physicists,
scientists,
radiopharmacists,
radiopharmaceutical
dosimetrists,
technologists,
nurse
managers,
totaling
240
30
countries.
Findings
revealed
prevailing
use
term
targeted
therapy,
with
52%
respondents
expressing
preference
this
term.
contrast,
approximately
37%
favored
"radiopharmaceutical
therapy,"
whereas
11%
"molecular
therapy."
Other
key
terms
under
umbrella
also
discussed
achieve
consensus
terminology.
dynamic
fluid
should
improve
communication
within
field,
better
reflect
technology
used,
enable
comparison
results,
ultimately
lead
improved
patient
outcomes.
Theranostics,
Год журнала:
2025,
Номер
15(10), С. 4368 - 4397
Опубликована: Март 18, 2025
Radioligand
therapy
(RLT)
has
garnered
significant
attention
due
to
the
recent
emergence
of
innovative
and
effective
theranostic
agents,
which
showed
promising
therapeutic
prognostic
results
in
various
cancers.
Moreover,
understanding
interaction
between
different
types
radiation
biological
tissues
is
essential
for
optimizing
interventions
These
concepts
directly
apply
clinical
RLTs
play
a
crucial
role
determining
efficacy
toxicity
profile
radiopharmaceutical
agents.
Personalized
dosimetry
powerful
tool
that
aids
estimating
patient-specific
absorbed
doses
both
tumors
normal
organs.
Dosimetry
RLT
an
area
active
investigation,
as
our
current
relationship
dose
tissue
damage
primarily
derived
from
external-beam
therapy.
Further
research
necessary
comprehensively
comprehend
this
context
RLTs.
In
present
review,
we
thorough
examination
involvement
177Lu/225Ac
radioisotopes
induction
direct
indirect
DNA
damage,
well
their
influence
on
initiation
repair
mechanisms
cancer
cells
neuroendocrine
metastatic
prostate
cancer.
Current
data
indicate
high-energy
α-emitter
can
impact
structure
by
causing
ionization,
leading
formation
ionized
atoms
or
molecules.
This
ionization
process
predominantly
leads
irreparable
intricate
double-strand
breaks
(DSBs).
On
other
hand,
majority
caused
β-emitter
indirect,
it
involves
production
free
radicals
subsequent
chemical
reactions.
Beta
particles
themselves
also
physically
interact
with
molecule,
resulting
single-strand
(SSBs)
potentially
reversible
DSBs.
